{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:29:29Z","timestamp":1769761769397,"version":"3.49.0"},"reference-count":38,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>One of the most commonly used anti-cancer agents, Cisplatin (CDDP) often causes nephrotoxicity by eliciting inflammation and oxidative stress. Golimumab, an anti-TNF biologic, is prescribed for the management of numerous inflammatory ailments like psoriatic and rheumatoid arthritis, ulcerative colitis and ankylosing spondylitis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Current study has explored the effects of anti-TNF biologics golimumab on mice due to cisplatin-induced nephrotoxicity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>Renal toxicity was caused by administration of single cisplatin injection at 22 mg\/kg by intraperitoneal (i\/p) route. Golimumab (24 mg\/kg, s.c.) was administered consecutively for 7 days. The parameters such as renal functions, oxidative stress, inflammation, and renal damage were evaluated on the 7th day of experiments.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Cisplatin administration caused nephrotoxicity as shown by a significant elevation of various parameters viz; serum creatinine, neutrophil gelatinase-associated lipocalin (NGAL), urea nitrogen (BUN), and cystatin C. There was a significant rise in urinary clusterin, kidney injury molecule 1 (KIM-1), and \u03b2-N-acetylglucosaminidase (NAG) concentrations in the animals treated with cisplatin. The markers of oxidative stress (malondialdehyde, reduced glutathione, and catalase), inflammation (IL-6, TNF-\u03b1, IL-10, IL-1\u03b2, MCP-1, ICAM-1, and TGF-\u03b21), and apoptosis (caspase-3) were also altered in serum and\/or kidneys of cisplatin animals. Further, cisplatin-caused histopathological changes in proximal tubular cells as observed in the H&amp;E staining of renal tissue. Golimumab treatment reduced all markers of kidney injury and attenuated cell death. Golimumab significantly reduced inflammatory cytokines TNF\u03b1, IL- 6, MCP-1, IL- 1\u03b2, ICAM-1, and TGF-\u03b21 and increased anti-inflammatory cytokine IL-10 in cisplatin-intoxicated mice.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The study\u2019s results suggest that golimumab prevented nephrotoxicity induced by cisplatin- through inhibition of oxidative stress, apoptotic cell death inflammatory response, thus improving renal function.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201022666210810141139","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T18:00:52Z","timestamp":1630951252000},"page":"970-977","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Amelioration of Cisplatin-induced Renal Inflammation by Recombinant Human Golimumab in Mice"],"prefix":"10.2174","volume":"23","author":[{"given":"Vishal","family":"Pavitrakar","sequence":"first","affiliation":[{"name":"Division of Biotechnology, Lupin Limited, Pune, India | Faculty of Health Sciences, Symbiosis School of Biological\nSciences, Selvan Ravindran, Symbiosis International (Deemed) University, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rustom","family":"Mody","sequence":"additional","affiliation":[{"name":"Division of Biotechnology, Lupin\nLimited, Pune, India (Currently associated with Sun Pharma Advanced Research Company Ltd., Vadodara, Gujarat,\nIndia)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6846-319X","authenticated-orcid":true,"given":"Selvan","family":"Ravindran","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Symbiosis School of Biological\nSciences, Selvan Ravindran, Symbiosis International (Deemed) University, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"Dasari S.","year":"2014","unstructured":"Dasari S.; Tchounwou P.B.; Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 2014,740,364-378","journal-title":"Eur J Pharmacol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1006\/taap.1997.8325","volume":"149","author":"Liu J.","year":"1998","unstructured":"Liu J.; Liu Y.; Habeebu S.S.; Klaassen C.D.; Metallothionein (MT)-null mice are sensitive to cisplatin-induced hepatotoxicity. Toxicol Appl Pharmacol 1998,149(1),24-31","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=3","first-page":"47","volume":"1","author":"Hanigan M.H.","year":"2003","unstructured":"Hanigan M.H.; Devarajan P.; Cisplatin nephrotoxicity: Molecular mechanisms. Cancer Ther 2003,1,47-61","journal-title":"Cancer Ther"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.13005\/bpj\/1250","volume":"10","author":"Saisruthi K.","year":"2017","unstructured":"Saisruthi K.; Sreedevi A.; Amelioration of Cisplatin-induced nephrotoxicity of roots of anthocephalus cadamba. Biomed Pharmacol J 2017,10(3),1433-1439","journal-title":"Biomed Pharmacol J"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.tox.2016.10.001","volume":"371","author":"Dugbartey G.J.","year":"2016","unstructured":"Dugbartey G.J.; Peppone L.J.; de Graaf I.A.; An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures. Toxicology 2016,371,58-66","journal-title":"Toxicology"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.5935\/0101-2800.20130052","volume":"35","author":"Peres L.A.","year":"2013","unstructured":"Peres L.A.; da Cunha A.D.; Acute nephrotoxicity of cisplatin: Molecular mechanisms. J Bras Nefrol 2013,35(4),332-340","journal-title":"J Bras Nefrol"},{"key":"ref=7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173339","volume":"884","author":"Okamoto K.","year":"2020","unstructured":"Okamoto K.; Saito Y.; Narumi K.; Furugen A.; Iseki K.; Kobayashi M.; Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo. Eur J Pharmacol 2020,884","journal-title":"Eur J Pharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","volume":"336","author":"Barnes P.J.","year":"1997","unstructured":"Barnes P.J.; Karin M.; Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997,336(15),1066-1071","journal-title":"N Engl J Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.etp.2008.09.003","volume":"61","author":"Chirino Y.I.","year":"2009","unstructured":"Chirino Y.I.; Pedraza-Chaverri J.; Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009,61(3),223-242","journal-title":"Exp Toxicol Pathol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1172\/JCI200215606","volume":"110","author":"Ramesh G.","year":"2002","unstructured":"Ramesh G.; Reeves W.B.; TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002,110(6),835-842","journal-title":"J Clin Invest"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4161\/mabs.1.5.9286","volume":"1","author":"Mazumdar S.","year":"2009","unstructured":"Mazumdar S.; Greenwald D.; Golimumab. MAbs 2009,1(5),422-431","journal-title":"MAbs"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/CEG.S48741","volume":"7","author":"L&#xF6;wenberg M.","year":"2014","unstructured":"L&#xF6;wenberg M.; de Boer N.Kh.; Hoentjen F.; Golimumab for the treatment of ulcerative colitis. Clin Exp Gastroenterol 2014,7,53-59","journal-title":"Clin Exp Gastroenterol"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3140680","volume":"2017","author":"Meng H.","year":"2017","unstructured":"Meng H.; Fu G.; Shen J.; Shen K.; Xu Z.; Wang Y.; Jin B.; Pan H.; Ameliorative effect of daidzein on cisplatin-induced nephrotoxicity in mice via modulation of inflammation, oxidative stress, and cell death. Oxid Med Cell Longev 2017,2017","journal-title":"Oxid Med Cell Longev"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.fct.2019.04.031","volume":"129","author":"Jing T.","year":"2019","unstructured":"Jing T.; Liao J.; Shen K.; Chen X.; Xu Z.; Tian W.; Wang Y.; Jin B.; Pan H.; Protective effect of urolithin a on cisplatin-induced nephrotoxicity in mice via modulation of inflammation and oxidative stress. Food Chem Toxicol 2019,129,108-114","journal-title":"Food Chem Toxicol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","volume":"22","author":"Crona D.J.","year":"2017","unstructured":"Crona D.J.; Faso A.; Nishijima T.F.; McGraw K.A.; Galsky M.D.; Milowsky M.I.; A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 2017,22(5),609-619","journal-title":"Oncologist"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","volume":"31","author":"Manohar S.","year":"2018","unstructured":"Manohar S.; Leung N.; Cisplatin nephrotoxicity: A review of the literature. J Nephrol 2018,31(1),15-25","journal-title":"J Nephrol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/toxins2112490","volume":"2","author":"Miller R.P.","year":"2010","unstructured":"Miller R.P.; Tadagavadi R.K.; Ramesh G.; Reeves W.B.; Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2010,2(11),2490-2518","journal-title":"Toxins (Basel)"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00210-018-1564-7","volume":"392","author":"Abdelrahman A.M.","year":"2019","unstructured":"Abdelrahman A.M.; Al Suleimani Y.; Shalaby A.; Ashique M.; Manoj P.; Nemmar A.; Ali B.H.; Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice. Naunyn Schmiedebergs Arch Pharmacol 2019,392(1),45-53","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2478\/acph-2020-0033","volume":"70","author":"Aljuhani N.","year":"2020","unstructured":"Aljuhani N.; Ismail R.S.; El-Awady M.S.; Hassan M.H.; Modulatory effects of perindopril on cisplatin-induced nephrotoxicity in mice: Implication of inflammatory cytokines and caspase-3 mediated apoptosis. Acta Pharm 2020,70(4),515-525","journal-title":"Acta Pharm"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejphar.2013.05.023","volume":"715","author":"Honma S.","year":"2013","unstructured":"Honma S.; Takahashi N.; Shinohara M.; Nakamura K.; Mitazaki S.; Abe S.; Yoshida M.; Amelioration of cisplatin-induced mouse renal lesions by a cyclooxygenase (COX)-2 selective inhibitor. Eur J Pharmacol 2013,715(1-3),181-188","journal-title":"Eur J Pharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/361078","volume":"2013","author":"Tsigou E.","year":"2013","unstructured":"Tsigou E.; Psallida V.; Demponeras C.; Boutzouka E.; Baltopoulos G.; Role of new biomarkers: Functional and structural damage. Crit Care Res Pract 2013,2013","journal-title":"Crit Care Res Pract"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1177\/0192623312444765","volume":"40","author":"Vinken P.","year":"2012","unstructured":"Vinken P.; Starckx S.; Barale-Thomas E.; Looszova A.; Sonee M.; Goeminne N.; Versmissen L.; Buyens K.; Lampo A.; Tissue Kim-1 and urinary clusterin as early indicators of cisplatin-induced acute kidney injury in rats. Toxicol Pathol 2012,40(7),1049-1062","journal-title":"Toxicol Pathol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1155\/MI.2005.139","volume":"2005","author":"Gonz&#xE1;lez R.","year":"2005","unstructured":"Gonz&#xE1;lez R.; Romay C.; Borrego A.; Hern&#xE1;ndez F.; Merino N.; Zamora Z.; Rojas E.; Lipid peroxides and antioxidant enzymes in cisplatin-induced chronic nephrotoxicity in rats. Mediators Inflamm 2005,2005(3),139-143","journal-title":"Mediators Inflamm"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/and.12197","volume":"46","author":"Aldemir M.","year":"2014","unstructured":"Aldemir M.; Okulu E.; K&#xF6;semehmeto&#x11F;lu K.; Ener K.; Topal F.; Evirgen O.; G&#xFC;rleyik E.; Avc\u0131 A.; Evaluation of the protective effect of quercetin against cisplatin-induced renal and testis tissue damage and sperm parameters in rats. Andrologia 2014,46(10),1089-1097","journal-title":"Andrologia"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.tox.2014.07.004","volume":"324","author":"Domitrovi\u0107 R.","year":"2014","unstructured":"Domitrovi\u0107 R.; Cvijanovi\u0107 O.; \u0160u\u0161ni\u0107 V.; Katalini\u0107 N.; Renoprotective mechanisms of chlorogenic acid in cisplatin-induced kidney injury. Toxicology 2014,324,98-107","journal-title":"Toxicology"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.cca.2006.06.011","volume":"375","author":"Ajith T.A.","year":"2007","unstructured":"Ajith T.A.; Usha S.; Nivitha V.; Ascorbic acid and alpha-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: A comparative study. Clin Chim Acta 2007,375(1-2),82-86","journal-title":"Clin Chim Acta"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.phrs.2009.07.007","volume":"60","author":"Khan S.A.","year":"2009","unstructured":"Khan S.A.; Priyamvada S.; Khan W.; Khan S.; Farooq N.; Yusufi A.N.; Studies on the protective effect of green tea against cisplatin induced nephrotoxicity. Pharmacol Res 2009,60(5),382-391","journal-title":"Pharmacol Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3109\/0886022X.2013.829405","volume":"35","author":"Sen S.","year":"2013","unstructured":"Sen S.; De B.; Devanna N.; Chakraborty R.; Cisplatin-induced nephrotoxicity in mice: Protective role of Leea asiatica leaves. Ren Fail 2013,35(10),1412-1417","journal-title":"Ren Fail"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1046\/j.1523-1755.2001.00043.x","volume":"60","author":"Deng J.","year":"2001","unstructured":"Deng J.; Kohda Y.; Chiao H.; Wang Y.; Hu X.; Hewitt S.M.; Miyaji T.; McLeroy P.; Nibhanupudy B.; Li S.; Star R.A.; Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 2001,60(6),2118-2128","journal-title":"Kidney Int"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/toxsci\/63.2.196","volume":"63","author":"Huang Q.","year":"2001","unstructured":"Huang Q.; Dunn R.T.; Jayadev S.; DiSorbo O.; Pack F.D.; Farr S.B.; Stoll R.E.; Blanchard K.T.; Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol Sci 2001,63(2),196-207","journal-title":"Toxicol Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/00007890-200003150-00049","volume":"69","author":"Lemay S.","year":"2000","unstructured":"Lemay S.; Rabb H.; Postler G.; Singh A.K.; Prominent and sustained up-regulation of gp130-signaling cytokines and the chemokine MIP-2 in murine renal ischemia-reperfusion injury. Transplantation 2000,69(5),959-963","journal-title":"Transplantation"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1172\/JCI119457","volume":"99","author":"Takada M.","year":"1997","unstructured":"Takada M.; Nadeau K.C.; Shaw G.D.; Marquette K.A.; Tilney N.L.; The cytokine-adhesion molecule cascade in ischemia\/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. J Clin Invest 1997,99(11),2682-2690","journal-title":"J Clin Invest"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1681\/ASN.V10112314","volume":"10","author":"Banas B.","year":"1999","unstructured":"Banas B.; Luckow B.; M&#xF6;ller M.; Klier C.; Nelson P.J.; Schadde E.; Brigl M.; Halevy D.; Holth&#xF6;fer H.; Reinhart B.; Schl&#xF6;ndorff D.; Chemokine and chemokine receptor expression in a novel human mesangial cell line. J Am Soc Nephrol 1999,10(11),2314-2322","journal-title":"J Am Soc Nephrol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"R922","DOI":"10.1152\/ajpregu.1999.277.3.R922","volume":"277","author":"Donnahoo K.K.","year":"1999","unstructured":"Donnahoo K.K.; Meng X.; Ayala A.; Cain M.P.; Harken A.H.; Meldrum D.R.; Early kidney TNF-alpha expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am J Physiol 1999,277(3),R922-R929","journal-title":"Am J Physiol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1046\/j.1523-1755.2001.00026.x","volume":"60","author":"Kaushal G.P.","year":"2001","unstructured":"Kaushal G.P.; Kaushal V.; Hong X.; Shah S.V.; Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int 2001,60(5),1726-1736","journal-title":"Kidney Int"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biologicals.2019.09.007","volume":"63","author":"Chahar D.S.","year":"2020","unstructured":"Chahar D.S.; Ravindran S.; Pisal S.S.; Monoclonal antibody purification and its progression to commercial scale. Biologicals 2020,63,1-13","journal-title":"Biologicals"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2174\/1389200220666190614150708","volume":"20","author":"Ravindran S.","year":"2019","unstructured":"Ravindran S.; Tambe A.J.; Suthar J.K.; Chahar D.S.; Fernandes J.M.; Desai V.; Nanomedicine: Bioavailability, biotransformation and biokinetics. Curr Drug Metab 2019,20(7),542-555","journal-title":"Curr Drug Metab"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2174\/1389200219666180305154119","volume":"19","year":"2018","unstructured":"CurrDrug Metab Ravindran, S.; Suthar, J.K.; Rokade, R.; Deshpande, P.; Singh, P.; Pratinidhi, A.; Khambadkhar, R.; Utekar, S. Pharmacokinetics, metabolism, distribution and permeability of nanomedicine.2018,19(4),327-334","journal-title":"CurrDrug Metab"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201022666210810141139","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/195496\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201022666210810141139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:11:39Z","timestamp":1655471499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/195496\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201022666210810141139","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}